Onxeo (Onxeo)

Oncology Corporate Profile

HQ Location

49 boulevard du G?en?eral Martial Valin
Paris, France 75015

Company Description

Onxeo was created through the merger of BioAlliance Pharma, a French innovative company based in Paris specializing in the development of drugs for orphan diseases in oncology, with Topotarget, a Danish biopharmaceuticals company based in Copenhagen, also a specialist in the development of oncology products.

Website: http://www.onxeo.com/en

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Livatag® / BA-003nanoparticle doxorubicinHepatocellular carcinoma (HCC)III
Clonidine Lauriad® / BA-028alpha 2 adrenoreceptor agonistOral mucositis with Head & Neck cancerII
AMEP® / BA-015anti-angiogenic and anti-proliferative peptide1st line metastatic MelanomaI
Fentanyl Lauriad® / BA-041Mu opioid receptor agonistCancer painI

View additional information on product candidates here »

Source: http://www.onxeo.com/en

Recent News Headlines

Sosei announces completion of Japanese Phase III clinical study of SO-1105 for oropharyngeal candidiasis and achievement of principal endpoints

8/29/2016 06:05 am

[at noodls] - Tokyo, Japan - 29 August 2016: Sosei Group Corporation (TSE Mothers Index: 4565) hereby announces that its Japanese subsidiary Sosei Co. Ltd. has completed the Japanese Phase III study of SO-1105 (miconazole ...